US 10828345

Here is a concise summary of US patent 10828345:

• Patent Number: US10828345B2
• Title: Use of a VEGF antagonist to treat angiogenic eye disorders
• Assignee: Regeneron Pharmaceuticals Inc.
• Inventor: George D. Yancopoulos
• Filing Date: 2018-10-12
• Issue Date: 2020-11-10
• Abstract: The patent describes methods for treating angiogenic eye disorders by sequentially administering multiple doses of a VEGF antagonist to a patient. The methods involve administering the VEGF antagonist at a frequency of once every 8 or more weeks, particularly when preceded by about three doses administered at a frequency of about 2 to 4 weeks. These methods are applicable to angiogenic eye disorders such as age-related macular degeneration, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, and corneal neovascularization.

Plain-Language Overview of Independent Claim(s):

• Claim 1: This claim outlines a method for treating an angiogenic eye disorder. It involves a specific sequential dosing regimen of a VEGF antagonist: an initial dose, followed by one or more secondary doses administered every 4 weeks after the previous dose, and then one or more tertiary doses administered every 12 weeks after the previous dose. The VEGF antagonist used in this method must be a receptor-based chimeric molecule, specifically comprising immunoglobulin-like (Ig) domain 2 from the Flt1 VEGF receptor, Ig domain 3 from the Flk1 VEGF receptor, and a component that allows it to form multimers.

CAFC 2026 Dockets:
As of April 26, 2026, a search for CAFC 2026 dockets specifically naming US patent 10828345 did not return any direct results. However, the patent family is involved in litigation. The provided patent document notes several ongoing legal proceedings, including PTAB cases (IPR2025-01269 and PGR2021-00035) and US District Court cases in West Virginia, New Jersey, and California. Additionally, US patent 10828345B2 is identified as one of several patents claiming priority in the "In re Aflibercept Patent Litigation MDL No. 3103". There is no authoritative information explicitly detailing any CAFC dockets specifically for US10828345 in 2026.